

## DAFTAR PUSTAKA

- Anderson, G.D., 2008, Gender Differences in Pharmacological Response, *Int. Rev. Neurobiol.*, **83** (8), 1–9.
- Anonim, 2019, Carboplatin, <http://chemocare.com/chemotherapy/drug-info/carboplatin.aspx>, 7 Mei 2019.
- Aronson, J.K. (Ed.), 2016, Platinum-Containing Cytostatic Drugs, dalam *Meyler's Side Effect of Drug*, Sixteenth Edition, 810-833 Elsevier Ltd., Oxford.
- Barrett-Lee, P.J., Bailey, N.P., O'Brien, M.E.R., dan Wager, E., 2000, Large-Scale UK Audit of Blood Transfusion Requirements and Anaemia in Patients Receiving Cytotoxic Chemotherapy, *Br. J. Cancer*, **82** (1), 93–97.
- Barrett-Lee, P.J., Ludwig, H., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P.A., Krzakowski, M., Nortier, J.W.R., Kongable, G., Schneider, M., Schrijvers, D., dan Belle, S.J. Van, 2006, Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey, *Oncology*, **70** (1), 34–48.
- Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E.F., Syrigos, K., Stahel, R., Felip, E., Peters, S., dan Members, P., 2014, 2nd ESMO Consensus Conference on Lung Cancer: Non-Small-Cell Lung Cancer First-Line/Second and Further Lines of Treatment in Advanced Disease, *Ann. Oncol.*, **25** (8), 1475–1484.
- Beutler, E. dan Waalen, J., 2019, The Definition of Anemia: What is the Lower Limit of Normal of the Blood Hemoglobin Concentration?, *Blood*, **107** (5), 1747–1751.
- Bittoni, M.A., Arunachalam, A., Li, H., Camacho, R., He, J., Zhong, Y., Lubiniecki, G.M., dan Carbone, D.P., 2018, Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study, *Clin. Lung Cancer*, **19** (5), e629–e645.
- Borg, C., Ray-coquard, I., Philip, I., Clapisson, G., Bendriss-vermare, N., Menetrier-caux, C., Sebban, C., Biron, P., dan Blay, J., 2004, CD4 Lymphopenia as a Risk Factor for Febrile Neutropenia and Early Death after Cytotoxic Chemotherapy in Adult Patients with Cancer, *Am. Cancer Soc.* **101** (11), 2675–2680.
- Bryer, E. dan Henry, D., 2018, Chemotherapy-Induced Anemia: Etiology, Pathophysiology, and Implications for Contemporary Practice, *Int. J. Clin. Transfus. Med.*, **6**, 21–31.

- Cao, S., Wang, S., Ma, H., Tang, S., Sun, C., Dai, J., Wang, C., Shu, Y., Xu, L., Yin, R., Song, X., Chen, H., Han, B., Li, Q., Wu, J., Bai, C., Chen, J., Jin, G., Hu, Z., Lu, D., dan Shen, H., 2016, Genome-Wide Association Study of Myelosuppression in Non-Small-Cell Lung Cancer Patients with Platinum-Based Chemotherapy, *Pharmacogenomics J.*, **16** (1), 41–46.
- Caro, J.J., Salas, M., dan Ward, A., Goss, G., 2001, Anemia as an Independent Prognostic Factor for Survival in Patients with Cancer a Systematic, Quantitative Review, *Am. Cancer Soc.*, **91** (12), 2214–2221.
- Chaumard, N., Limat, S., Villanueva, C., Nerich, V., Fagnoni, P., Bazan, F., Chaigneau, L., Dobi, E., Cals, L., dan Pivot, X., 2012, Incidence and Risk Factors of Anemia in Patients with Early Breast Cancer Treated by Adjuvant Chemotherapy, *Breast*, **21**, 464–467.
- Cheng, K., Zhao, F., Gao, F., Dong, H., Men, H.-T., Chen, Y., Li, L.-H., Ge, J., Tang, J., Ding, J., Chen, X., Du, Y., Luo, W.-X., dan Liu, J.-Y., 2013, Factors Potentially Associated with Chemotherapy-Induced Anemia in Patients with Solid Cancers, *Asian Pacific J. Cancer Prev.*, **13** (10), 5057–5061.
- Cheng, Y., Wu, R., Cheng, M., Du, J., Hu, X., Yu, L., Zhao, X., Yao, Y., Long, Q., Zhu, L., Zhu, J., Huang, N., Liu, H., Hu, Y., dan Wan, F., 2017, Carboplatin-Induced Hematotoxicity among Patients with Non-Small Cell Lung Cancer: Analysis on Clinical Adverse Events and Drug-Gene Interactions, *Oncotarget*, **8** (19), 32228–32236.
- Chinese Society of Clinical Oncology, 2012, Clinical Practice Guidelines on Cancer-Related Anemia (2012-2013 Edition), *Chinese Clin. Oncol.*, **1** (2), 1–21.
- D’Addario, G., dan Felip, E., 2009, Non-Small-Cell Lung Cancer: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-up, *Ann. Oncol.*, **20** (SUPPL. 4), 68–70.
- Davidov, D., 2012, The Hemoglobin Level as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer Treated with Gemcitabine and cis-Platinum, *J. IMAB - Annu. Proceeding (Scientific Pap)*, **18**, 209–212.
- DiPiro, C. V. (Ed.), 2012, Lung Cancer, dalam *Pharmacotherapy Handbook*, 619–664, McGraw Hill, New York.
- Direktorat Bina Pelayanan Kefarmasian, 2011, *Pedoman Interpretasi Data Klinik*, Kementerian Kesehatan RI, Jakarta.
- Ettinger, D.S., Wood, D.E., Akerley, W., Bazhenova, L.A., Borghaei, H., Camidge, D.R., Cheney, R.T., Chirieac, L.R., D’Amico, T.A., Dilling, T.J., Dobelbower, M.C., Govindan, R., Grannis, F.W., Hennon, M., Horn, L., Jahan, T.M., Komaki, R., Lackner, R.P., Lanuti, M., Lilenbaum, R., Lin, J., Loo, B.W., Martins, R., Otterson, G.A., Patel, J.D., Pisters, K.M., Reckamp, K., Riely,

- G.J., Schild, S.E., Shapiro, T.A., Sharma, N., Stevenson, J., Swanson, S.J., Tauer, K., Yang, S.C., Gregory, K., dan Hughes, M., 2016, *NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer Version 3.2016*, National Comprehensive Cancer Network.
- Frieze, D.A. dan Adams, V.R., 2011, Lung Cancer, dalam Dipiro, J.T., Talbret, R.L., Yee, G.C., Matzke, G.L., Barbara G. Wells, dan Posey, L.M. (Eds.), *Pharmacotherapy A Pathophysiologic Approach*, 8th Edition, 2271-2285, The Mc-Graw Hill Companies Inc., New York.
- Gabrielson, E., 2006, Invited Review Series: Lung Cancer Worldwide Trends in Lung Cancer Pathology, *Respirology*, **11** (5), 533–538.
- Gao, F., Cheng, K., Zhao, F., Chen, Y., Li, L., Dong, H., Ge, J., Tang, J., Ding, J., Chen, X., Su, J., dan Liu, J., 2011, Prevalence and Characteristics of Anemia in Patients with Solid Cancers at Diagnosis in Southwest China, *Asian Pacific J. Cancer Prev.*, **12** (11), 2825–2828.
- Ginsberg, R.J., Vokes, E.E., dan Rosenzweig, K., 2001, Non-Small Cell Lung Cancer, dalam Devita, V.T., Hellman, S., dan Rosenberg, S.A. (Eds.), *Cancer: Principles and Practice of Oncology*, Lippincott Williams & Wilkins.
- Grabowski, J.P., Richter, R., Rittmeister, H., Chekerov, R., Woopen, H., dan Sehouli, J., 2018, Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients, *Anticancer Res.*, **38** (10), 5853–5858.
- Gridelli, C., Rossi, A., Carbone, D.P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., dan Rosell, R., 2015, Non-Small-Cell Lung Cancer, *Nat. Rev. Dis. Prim.*, **1**, 1–16.
- Gutierrez, F., Gonzalez-de-la-Fuente, G.A., Nazco, G.J., Oramas, J., dan Batista, N., 2016, Hematological Toxicity of Carboplatin for Gynecological Cancer According to Body Mass Index, *Eur. J. Clin. Pharmacol.*, **72** (9), 1083–1089.
- Hardy, D., Cormier, J.N., Xing, Y., Liu, C.-C., Xia, R., dan Du, X.L., 2010, Chemotherapy-Associated Toxicity in a Large Cohort of Elderly Patients with Non-small Cell Lung Cancer, *J. Thorac. Oncol.*, **5** (1), 90–98.
- Hassan, B.A.R., Yusoff, Z.B.M., Hassali, M.A., dan Othman, S. Bin, 2011, Association and Correlation of Different Chemotherapeutic Regimens and Doses With Onset and Severity of Anemia Among Solid Cancer Patients, *Asian Pasific J Cancer Prev.*, **12** (10), 2753–2758.
- Horn, L., Eisenberg, R., Gius, D., Kimmelschue, K.N., Massion, P.P., Putnam, J.B., Robinson, C.G., dan Carbone, D.P., 2013, Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer, dalam *Abeloff's Clinical Oncology*, Fifth Edition, 1143-1192, Elsevier Inc.

International Agency for Research on Cancer (IARC), 2018, *Indonesia Fact Sheet*, <http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>, 26 Februari 2019.

Jiang, N., Chen, X.-C., dan Zhao, Y., 2013, Analysis of the Risk Factors for Myelosuppression After Concurrent Chemoradiotherapy for Patients with Advanced Non-Small Cell Lung Cancer, *Support. Care Cancer*, **21** (3), 785–791.

Johnson, D.H., 2000, Evolution of Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer, *Chest*, **117** (4 SUPPL. 1), 133S–137S.

Kawahara, M., Atagi, S., Komuta, K., Yoshioka, H., Kawasaki, M., Fujita, Y., Yonei, T., Ogushi, F., Kubota, K., Nogami, N., Tsuchiya, M., Shibata, K., Tomizawa, Y., Minato, K., Fukuoka, K., Asami, K., dan Yamanaka, T., 2013, Carboplatin Plus either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-Small Cell Lung Cancer, *Anticancer Res.*, **33** (10), 4631–4638.

Komite Penanggulangan Kanker Nasional, 2017<sup>a</sup>, *Panduan Penatalaksanaan Kanker Paru*, Kementerian Kesehatan RI, Jakarta.

Komite Penanggulangan Kanker Nasional, 2017<sup>b</sup>, *Pedoman Nasional Pelayanan Kedokteran Kanker Paru*, Kementerian Kesehatan RI, Jakarta.

Kosmidis, P., 2002, Chemotherapy in NSCLC: Historical Review, *Lung Cancer*, **38** (Suppl 3), 19–22.

Kosmidis, P. dan Krzakowski, M., 2005, Anemia Profiles in Patients with Lung Cancer: What Have We Learned from the European Cancer Anaemia Survey (ECAS)?, *Lung Cancer*, **50** (3), 401–412.

Kratzke, R.A. dan Patel, M.R., 2018, Primary Lung Cancer, dalam Kellerman, R.D., dan Bope, E.T. (Eds.), *Conn's Current Therapy 2018*, 826-831 Elsevier Ltd., Philadelphia.

Kurnianda, J., Wiyadi, N., dan Wulaningsih, W., 2008, Risk Factors of Anemia in Head and Neck Cancer Patients Undergoing Chemotherapy with High-Dose Cisplatin, *Med. J. Indones.*, **17** (4), 248–254.

Latimer, K.M. dan Mott, T.F., 2015, Lung Cancer: Diagnosis, Treatment Principles, and Screening, *Am. Fam. Physician*, **91** (4), 250–256.

Lemeshow, S., Jr, D.W.H., Klar, J., dan Lwanga, S.K., 1990, *Adequacy of Sample Size in Health Studies, Technometrics*, John Wiley and Sons, Chicester.

Lheureux, S., Clarisse, B., Launay-Vacher, V., Gunzer, K., Delcambre-Lair, C., Bouhier-Leporrier, K., Kaluzinski, L., Maron, D., Ngo, M.-D., Grossi, S., Dubois, B., Zalcman, G., dan Joly, F., 2011, Evaluation of Current Practice:

Management of Chemotherapy-Related Toxicities, *Anticancer. Drugs*, **22** (9), 919–925.

Liew, M.S., Sia, J., Starmans, M.H.W., Tafreshi, A., Harris, S., Feigen, M., White, S., Zimet, A., Lambin, P., Boutros, P.C., Mitchell, P., dan John, T., 2013, Comparison of Toxicity and Outcomes of Concurrent Radiotherapy with Carboplatin/Paclitaxel or Cisplatin/Etoposide in Stage III Non-Small Cell Lung Cancer, *Cancer Med.*, **2** (6), 916–924.

Ludwig, H., 2006, Prevalence and Incidence of Anemia and Risk Factors for Anemia in Patients with Cancer, dalam Nowrousian (Ed.), *Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology*, 189–206, Springer, Vienna.

Ludwig, H., Wedding, U., dan Van Belle, S., 2012, Anaemia in Elderly Patients with Cancer: Focus on Chemotherapy-Induced Anaemia, *J. Geriatr. Oncol.*, **3** (3), 256–264.

Mandal, R., Kalke, R., dan Li, X., 2004, Interaction of Oxaliplatin, Cisplatin, and Carboplatin with Hemoglobin and the Resulting Release of a Heme Group, *Chem. Res. Toxicol.*, **17** (10), 1391–1397.

Marec-berard, B.P., Blay, J.Y., Schell, M., Buclon, M., Demaret, C., dan Raycoquard, I., 2003, Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients, *J. Clin. Oncol.*, **21** (22), 4235–4238.

Medina, P.J. dan Shord, S.S., 2011, Cancer Treatment and Chemotherapy, dalam DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., dan Posey, L.M. (Eds.), *Pharmacotherapy A Pathophysiologic Approach*, 8th Edition, 2191–2227, McGraw Hill, New York.

Mudad, R., Patel, M.B., Margunato-Debay, S., Garofalo, D., dan Lal, L.S., 2017, Comparative Effectiveness and Safety of nab-Paclitaxel Plus Carboplatin vs Gemcitabine Plus Carboplatin in First-Line Treatment of Advanced Squamous Cell Non-Small Cell Lung Cancer in a US Community Oncology Setting, *Lung Cancer Targets Ther.*, **8**, 179–190.

National Cancer Institute, 2017, *Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0*. US Department of Health and Human Services.

Nie, X., Liu, D., Li, Q., dan Bai, C., 2013, Predicting Chemotherapy Toxicity in Older Adults with Lung Cancer, *J. Geriatr. Oncol.*, **4** (4), 334–339.

Paz-Ares, L.G., De Marinis, F., Dediu, M., Thomas, M., Pujol, J.L., Bidoli, P., Molinier, O., Sahoo, T.P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A.H., Visseren-Grul, C., dan Gridelli, C., 2013, PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately after Induction



Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer, *J. Clin. Oncol.*, **31** (23), 2895–2902.

Pelosof, L., Ahn, C., Gao, A., Horn, L., Madrigales, A., Cox, J., McGavic, D., Minna, J.D., Gazdar, A.F., dan Schiller, J., 2017, Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions, *J. Natl. Cancer Inst.*, **109** (7), 1–6.

Qahtani, S.A. Al, 2018, Drug-Induced Megaloblastic, Aplastic, and Hemolytic Anemias: Current Concepts of Pathophysiology and Treatment, *Int J Clin Exp Med.*, **11** (6), 5501–5512.

Rodgers, G.M., Becker, P.S., Blinder, M., Cella, D., Chanan-Khan, A., Cleeland, C., Coccia, P.F., Djulbegovic, B., Gilreath, J.A., Kraut, E.H., Matulonis, U.A., Millenson, M.M., Reinke, D., Rosenthal, J., Schwartz, R.N., dan Soff, G., 2012, Cancer- and Chemotherapy-Induced Anemia Clinical Practice Guidelines in Oncology, *J. Natl. Compr. Cancer Netw.*, **10** (5), 628–653.

Shead, D.A., Hanisch, L.J., Clarke, R., dan Corrigan, A., 2018, *NCCN Guidelines for Patients Lung Cancer - Non-Small Cell*, National Comprehensive Cancer Network.

Sutandyo, N. dan Suratman, E., 2018, Non-Small Cell Lung Carcinoma in Women : A Retrospective Cohort Study in Indonesia, *Acta Med Indones - Indones J Intern Med*, **50** (4), 291–298.

Treat, J.A., Gonin, R., Socinski, M.A., Edelman, M.J., Catalano, R.B., Marinucci, D.M., Ansari, R., Gillenwater, H.H., Rowland, K.M., Comis, R.L., Obasaju, C.K., dan Belani, C.P., 2010, A Randomized, Phase III Multicenter Trial of Gemcitabine in Combination with Carboplatin or Paclitaxel versus Paclitaxel plus Carboplatin in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer, *Ann. Oncol.*, **21** (3), 540–547.

Vasey, P.A., Jayson, G.C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., dan Kaye, S.B., 2004, Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma, *J. Natl. Cancer Inst.*, **96** (22), 1682–1691.

Wahbah, M., Boroumand, N., Castro, C., El-Zeky, F., dan Eltorky, M., 2007, Changing Trends in the Distribution of the Histologic Types of Lung Cancer: a Review of 4,439 Cases, *Ann. Diagn. Pathol.*, **11** (2), 89–96.

Wang, Y., Chen, J., Wu, S., Hu, C., Li, X., Wang, Y., Yang, Y., Rajan, N., Chen, Y., Chen, Y., Luo, Z., dan Chen, W., 2014, Clinical Effectiveness and Clinical Toxicity Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in Chinese Patients: a Retrospective Cohort Study, *BMC Cancer*, **14** (940), 1–17.

Yılmaz, U.M., Erol, S., Yalçın, B., Anar, C., Özdoğan, Y., Gürlek, Ü., dan Yılmaz, H., 2015, Chemoradiotherapy-Associated Myelosuppression: A Retrospective Analysis of Risk Factors for Patients with Non-Small Cell Lung Cancer, *Eurasian J Pulmonol*, **17**, 49–53.